At Jounce, we are driven by the desire to create long-lasting therapeutic options to transform the way cancer is treated. This is brought to life by our Cancer Hero Wall – a daily reminder of why we come to work each day and the potential impact we can have on patients’ lives.

We factor patients into every step of developing cancer therapies. We conduct biomarker analyses of patient populations in clinical trials with an aim to match the right immunotherapy to the right patients. We track patient outcomes from clinical trials and correlate this with biomarkers throughout clinical development, a process we call our reverse translational approach.

The potential benefit of our approach for cancer patients is two-fold: shorter development times to deliver novel therapies to patients with unmet needs and improved treatment outcomes.

It is our goal to make a meaningful and long-lasting impact on the lives of cancer patients.

Hero Wall

Jounce Cancer Hero Wall

Why we do what we do:

Jouncers describe what motivates them each day

Mobilizing the Immune System to Attack Cancer

Based on the groundbreaking initial research and discoveries by our founders, including Dr. Jim Allison, a Nobel laureate for this work, we aim to revolutionize the immunotherapy field. Using our Translational Science Platform, focused on targeting the alteration of the composition of immune cells within the human tumor microenvironment (TME), our goal is to transform the treatment of cancer by developing therapies that enable the immune system to attack tumors and bring long-lasting benefits to patients.

The TME refers to the cellular environment that makes up a tumor, which includes blood vessels, immune cells, fibroblasts, myeloid cells (including tumor-associated macrophages), lymphocytes, signaling molecules and the extracellular matrix.

Our approach to identifying novel targets and mechanisms is broadly applicable and can work with multiple cell types in the TME.


What makes us different


Advancing a pipeline of innovative cancer therapies

Immunotherapies have been increasingly recognized as critical components of cancer therapy and have begun to fundamentally change the paradigm for treating patients. However, due to a general lack of predictive biomarkers that identify patient populations most likely to respond to treatments, there is still a significant unmet need for better treatment outcomes.

Developing immunologic insights into tumors to match THE RIGHT THERAPIES TO THE RIGHT PATIENTS


Our Translational Science Platform and reverse translational analysis allow us to ask and answer important scientific and clinical questions.

We utilize a suite of integrated technologies to profile the immune cellular and molecular characteristics within thousands of human solid tumors. Through these analyses, we are provided with critical information about the TME, allowing us to better understand the complexities of the immune system, as well as identify and guide new immunotherapies through development more efficiently.

Our systematic approach matches targets to defined patient populations that we believe are more likely to benefit from these therapies and distinguishes and prioritizes targets. Target discovery is at the core of Jounce science. Our Translational Science Platform and discovery engine provide us with both the expertise and efficiency to develop promising and differentiated immune-oncology assets.

We believe that we can facilitate a systematic means of novel immunotherapy discovery, enroll biomarker-defined patient populations in clinical trials, and develop therapies that, alone or in combination, will have a meaningful and long-lasting impact on the lives of cancer patients.


JTX-8064 Mono and combination dose escalation complete, initiation of expanded tumor specific cohorts

INNATE: JTX-8064 monotherapy and pimivalimab combination dose escalation complete (Sep/Oct), initiation of expanded tumor specific cohorts


Initiated INNATE Trial of JTX-8064 (LILRB2/ILT4 inhibitor) +/- Pimivalimab (PD-1 inhibitor)

Initiated INNATE Trial of JTX-8064 (LILRB2/ILT4 inhibitor) +/- Pimivalimab (PD-1 inhibitor)


Initiated SELECT Trial of Pimivalimab (PD-1 inhibitor) +/- Vopratelimab (ICOS agonist)

Initiated SELECT Trial of Pimivalimab (PD-1 inhibitor) +/- Vopratelimab (ICOS agonist)


License Agreement with Gilead Sciences

License Agreement with Gilead Sciences

  • Licensed worldwide rights to JTX-1811 following IND clearance


Regained the worldwide rights to JTX-8064 from Bristol Myers Squibb

Regained the worldwide rights to JTX-8064 from Bristol Myers Squibb

  • Wholly-owned program advances our mission to discover new immunotherapies from a variety of immune cell types


Thomas Gajewski

Congratulations to Thomas Gajewski, recipient of the 2019 ESMO Award for Immuno-Oncology


Updated strategic collaboration with Celgene

  • Licensed worldwide rights to JTX-8064
  • Retained full worldwide rights to vopratelimab, JTX-4014 and all discovery programs


Vopratelimab EMERGE clinical trial initiation


Nobel Prize in Physiology or Medicine

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation


Padmanee Sharma

Jounce Therapeutics co-founder Padmanee Sharma, M.D., Ph.D. awarded the William B. Coley Award for Distinguished Research in Tumor Immunology for her innovative work understanding factors that enhance and hinder cancer immunotherapy.


Pricing of IPO


Major strategic collaboration with Celgene to develop next-generation immuno-oncology therapies


Jim Allison

Jounce founder, Jim Allison receives the Lasker-DeBakey Clinical Medical Research Award



Vopratelimab ICONIC trial initiation

August 2015

Keytruda and Opdivo

Keytruda® and Opdivo® (Anti-PD-1), (immune checkpoint therapies) approved; additional clinical trials indicate activity in several cancers


Jounce expands application

Jounce expands application of translational science platform to Beyond T cells and initiates series of programs targeting myeloid and other cell types


Jounce Launches

Jounce launched by Third Rock Ventures and founders, James P. Allison, Ph.D., Thomas F. Gajewski, M.D., Ph.D., Drew Pardoll, M.D., Ph.D, Robert Schreiber, Ph.D, Padmanee Sharma, M.D., Ph.D., Louis M. Weiner, M.D.

February 2013


Yervoy® anti-CTLA-4 approved for advanced melanoma


jounce founders publish

Brad Carthon and Jounce founders Pam Sharma and Jim Allison’s publication on enhanced survival related to up-regulation of ICOS on T cells in Clinical Cancer Research


preclinical evidence ctla-4

Preclinical evidence from Jim Allison of enhanced anti-tumor immunity by CTLA-4 published in Science


pd-1 receptor

PD-1 receptor (immune checkpoint) identified by Tasuku Honjo


Scroll to Learn More